The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis

Abstract

Background: Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax malaria. The mechanism of action and the optimal dosing - a balance between haemolytic risk and radical cure efficacy - are uncertain. Methods: We pooled individual data from 1,102 patients with acute vivax malaria and 72 healthy volunteers (all with >70% of the population median whole blood glucose-6-phosphate dehydrogenase [G6PD] activity) who were studied in the pre-registration trials of tafenoquine. Plasma tafenoquine concentrations were analysed under a population pharmacokinetic model. A series of Bayesian logistic and Emax dose-response models were fitted to the primary outcome of any P. vivax recurrence within 4 months. Acute vomiting and haemolysis were secondary outcomes. The key exposure variables were: the mg/kg tafenoquine dose; pharmacokinetic summaries of parent compound exposure (AUC[0,∞], Cmax) and metabolism (terminal elimination half-life); and day 7 methaemoglobin concentration (%) as a measure of oxidative activity. Results Tafenoquine dose (mg/kg) was a major determinant of recurrence (odds ratio [OR]: 0.70 per mg/kg increase, 95% credible interval [CI]: 0.65-0.75). After adjustment for dose, the tafenoquine terminal elimination half-life (OR: 1.15 per day increase, 95% CI: 1.06-1.25), and the day 7 methaemoglobin concentration (OR: 0.81 per absolute percentage point increase, 95% CI: 0.65 to 0.99), but not the parent compound exposure, were also associated with recurrence. Under the Emax model we estimate that the currently recommended 300mg dose in a 60kg adult (5mg/kg) results in approximately 70% of the maximal obtainable hypnozoiticidal effect. Increasing the dose to 7.5mg/kg (i.e. 450mg) would result in 90% reduction in the risk of P. vivax recurrence. Tafenoquine was well tolerated. No patients had severe haemolysis. Acute vomiting was not dose-related. In patients with normal G6PD enzyme concentrations, tafenoquine dose was associated with minor post-treatment haemoglobin reductions on days 2 or 3 (0.02 g/dL per mg/kg increase [95% CI: 0.04 to 0.00]). Conclusions and interpretation The currently recommended 300mg adult dose for radical cure of vivax malaria has suboptimal efficacy. Increasing to 450mg is predicted to increase radical cure rates substantially. The production of oxidative metabolites is central to tafenoquine's hypnozoiticidal efficacy. Clinical trials of higher tafenoquine doses are now needed to characterise efficacy, safety and tolerability.

Competing Interest Statement

JAG and GCJWK were formerly employees of GlaxoSmithKline who funded the pre-registration studies of tafenoquine.

Funding Statement

NJW is a principal research fellow funded by the Wellcome Trust (093956/Z/10/C). JAW is a Sir Henry Dale Fellow funded by the Wellcome Trust (223253/Z/21/Z). RJC is funded by an Australian National Health and Medical Research (NHMRC) Emerging Leader Investigator Grant (1194702). RNP is a Wellcome Trust Senior Fellow in Clinical Science (200909). JAS is funded by an Australian NHMRC Leadership Investigator Grant (1196068).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Anonymised individual patient data were obtained via ClinicalStudyDataRequest.com following approval of a research proposal from the Independent Review Panel. Re-use of existing, appropriately anonymized, human data does not require ethical approval under the Oxford Tropical Research Ethics Committee regulations (OxTREC).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

留言 (0)

沒有登入
gif